In obese people with low growth hormone taking tesamorelin, the link between higher IGF-I and better muscle energy recovery is even stronger than in the whole group of participants.
Scientific Claim
Among obese adults with reduced growth hormone secretion treated with tesamorelin, increases in insulin-like growth factor I (IGF-I) levels correlate more strongly with improvements in phosphocreatine recovery rate (ViPCr) (R=0.71, P=0.03) than in the overall study population (R=0.56).
Original Statement
“The association between IGF-I and PCr recovery was even stronger among subjects treated with tesamorelin only (ViPCr: R=0.71; P=.03).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The study design supports correlational claims. The phrasing 'correlate more strongly' accurately describes the observed difference in correlation coefficients between subgroups.
Evidence from Studies
Supporting (1)
The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.